Health Care·Biotechnology·$7.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.21 | N/A | +48.78% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.21 | N/A | +48.78% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the quarter's performance, particularly in terms of EPS. They emphasized their commitment to ongoing clinical development.
We are pleased with our progress in the quarter.
Our focus remains on advancing our clinical programs.
ImmunityBio's earnings report showed a significant beat on EPS, which likely contributed to the positive stock reaction, rising 4.63%. The company did not provide revenue figures or future guidance, leaving investors to focus on the EPS performance and management's optimistic tone regarding clinical advancements.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
COCA COLA CONSOLIDAT
May 11, 2021